Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Nova Eye Medical ( (AU:EYE) ) is now available.
Nova Eye Medical reported record half-year revenue of A$16.7 million for the six months to 31 December 2025, equivalent to US$11 million and up 31% in constant currency. Growth was led by the U.S. market and stronger performance in the rest of the world, driving last-twelve-month sales to A$32.2 million, roughly three times the estimated growth rate of the glaucoma surgical devices industry.
The company substantially improved its operating result, narrowing its EBITDA loss to A$2.2 million from A$4.2 million a year earlier on the back of higher gross margins, operating leverage and cost control. Nova Eye achieved positive EBITDA in December 2025, reaffirmed its FY26 guidance for sales of US$21–24 million excluding China, and signalled a path toward breakeven EBITDA in the second half of FY26, underscoring improving cash generation and operating momentum.
The most recent analyst rating on (AU:EYE) stock is a Hold with a A$0.17 price target. To see the full list of analyst forecasts on Nova Eye Medical stock, see the AU:EYE Stock Forecast page.
More about Nova Eye Medical
Nova Eye Medical is an Australian-listed ophthalmic device company focused on surgical treatments for glaucoma. The company generates most of its revenue from the United States while also expanding in Europe and the rest of the world, with China contributing a smaller and currently declining share of group sales.
Average Trading Volume: 465,106
Technical Sentiment Signal: Hold
Current Market Cap: A$45.57M
Find detailed analytics on EYE stock on TipRanks’ Stock Analysis page.